Immunostimulating interstitial laser thermotherapy (imILT) is
a treatment protocol for solid tumours developed to destroy the
tumour at the treatment site while simultaneously inducing an
immunologically mediated systemic response against the treated
tumour type. In this article, Jakob Axelsson, Cristina Pantaleone
and Stefan Åström of Clinical Laserthermia Systems AB define
how previously clinical treatment data of the method has been
presented, and in this progress report a broader array of indications
are described. It details the initial findings of the clinical study
programme designed to evaluate the safety and usability of the
equipment.